source
- Experimental drugs to lower Lp(a) move toward market, promising billions in potential salesHigh levels of lipoprotein(a), or Lp(a), are a genetic risk factor for heart disease that affects roughly one in five people and currently has no approved therapy. Several drugmakers are moving ex…
- U.S. Employers Plan to Drop GLP-1 Drug Coverage, Survey Shows 14% Will Cut Benefits by 2027About 14% of U.S. employers have already decided or intend to stop covering GLP-1 medicines by 2027, according to a Reuters‑cited Business Group on Health survey. The shift reflects growing concern…